Bio-S: Subsidiary Saimo Pharmaceutical plans to win bids for 12 varieties in the 11th national drug procurement

Zhitong
2025.11.04 00:59

On November 3rd, Bio-S stated during a research visit by five institutions including Hongdao Investment and Yongquan Investment that its subsidiary, Saimo Pharmaceutical, has a construction area of approximately over 260 acres, with 163,000 square meters of GMP-standard pharmaceutical plants and supporting laboratories completed. A total of 617 projects have been verified for implementation, and 461 projects have been registered, ranking among the top in the country. In the 11th batch of national centralized drug procurement, Saimo Pharmaceutical has 12 varieties proposed for bidding, with 4 products as the marketing authorization holders and 8 products as the entrusted manufacturers. This proposed bidding demonstrates Saimo Pharmaceutical's production capacity and market competitiveness, and will accelerate the release of Saimo Pharmaceutical's production capacity in the future, further enhancing its market share

Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
© 2025 Longbridge｜Disclaimer